Methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. When used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal acti...
The average adult dose is 4 g a day given as one 1000 mg tablet or two 500 mg tablets after each meal and at bedtime. Children 6 to 12 years of age should receive half the adult dose; one 500 mg tablet, 4 times a day.
Rx Only
Methenamine mandelate, a urinary antibacterial agent, is the chemical combination of mandelic acid with methenamine. Methenamine mandelate is available for oral use as film-coated tablets.
Each Methenamine mandelate 500mg tablet contains the following inactive ingredients: Caramel, Carmine, Croscarmellose Sodium, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Silicon Dioxide, Spirulina Extract, Talc, Titanium Dioxide.
Each Methenamine mandelate 1000mg tablet contains the following inactive ingredients: Croscarmellose Sodium, Ferric Oxide Red, Ferric Oxide Yellow, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Silicon Dioxide, Talc, Titanium Dioxide.
Methenamine mandelate is readily absorbed but remains essentially inactive until it is excreted by the kidneys and concentrated in the urine. An acid urine is essential for antibacterial action, with maximum efficacy occurring at pH 5.5 or less. In an acid urine, mandelic acid exerts its antibacterial action and also contributes to the acidification of the urine. Mandelic acid is excreted both by glomerular filtration and tubular excretion. The methenamine component is hydrolyzed in acid urine to ammonia and to the bactericidal agent formaldehyde.
Proportionally less formaldehyde is released as urinary pH approaches 6.0 and insufficient quantities are released above this level for therapeutic response. There is equally effective antibacterial activity against both gram-positive and gram-negative organisms, since the antibacterial action of mandelic acid and formaldehyde is nonspecific. There are reports that methenamine mandelate is ineffective in some infections with Proteus vulgaris and urea-splitting strains of Pseudomonas aeruginosa and A. aerogenes. Since urea-splitting strains may raise the pH of the urine, particular attention to supplementary acidification with agents such as ascorbic acid, and urinary pH monitoring is required. However, results in any single case will depend to a large extent on the underlying pathology and the overall management.
Methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. When used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate because of the nonspecific effect of formaldehyde formed in an acid urine.
Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growthsupporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis.
Methenamine mandelate helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate.
Methenamine mandelate tablets are contraindicated in patients with renal insufficiency, severe hepatic disease, severe dehydration, and in patients who have exhibited hypersensitivity to any components of this product.
Methenamine mandelate should be avoided in patients with gout because it may precipitate urate crystals in their urine. A similar situation may arise in patients with a predisposition to the formation of uric acid stones.
Methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.
Dysuria may occur (usually at higher than recommended dosage). This can be controlled by reducing the dosage and the acidification. When urine acidification is contraindicated or unattainable (as with some urea-splitting bacteria), the drug is not recommended.
Large doses of methenamine (8 g daily for 3 to 4 weeks) have caused bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.
To assure an acidic pH, patients should be instructed to restrict or avoid milk products and antacids containing sodium carbonate or bicarbonate.
As with all urinary tract infections, the efficacy of therapy should be monitored by repeated urine cultures. Urinary pH monitoring is required to assure an acidic urinary pH (below 5.5).
Formaldehyde and sulfamethizole form an insoluble precipitate in acid urine; therefore, methenamine mandelate should not be administered concurrently with sulfamethizole or other sulfonamides. Concurrent use of salicylates may lead to increased serum salicylate levels since excretion of salicylates is reduced in acidified urine.
Formaldehyde interferes with fluorometric procedures for determination of urinary catecholamines and vanillylmandelic acid (VMA), causing erroneously high results. Formaldehyde also causes falsely decreased urine estriol levels by reacting with estriol when acid hydrolysis techniques are used; estriol determinations which use enzymatic hydrolysis are unaffected by formaldehyde.
Formaldehyde causes falsely elevated 17-hydroxycorticosteroid levels when the Porter-Silber method is used and falsely decreased 5-hydroxyindoleacetic acid (5HIAA) levels by inhibiting color development when nitrosonaphthol methods are used.
Methenamine mandelate has not been evaluated for carcinogenicity or mutagenicity.
Methenamine was evaluated for mutagenicity in the Ames Salmonella/mammalian microsome test. Five strains of Salmonella typhimurium (TA98, TA100, TA1535, TA1537 and TA1538) and a strain of Escherichia coli (WP2uvrA) were used. At a dose of 10,000 μg/plate methenamine showed mutagenic activity in Salmonella typhimurium TA98 and TA100 by metabolic activation and also showed mutagenic activity in TA98 without microsomal activation.
In one large study, no evidence of carcinogenicity was found following long-term oral administration of methenamine 1.25 g/kg/day to rats (104 weeks) and mice (60 weeks).
Animal reproduction studies have not been conducted with methenamine mandelate. It is also not known whether methenamine mandelate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Since methenamine is known to cross the placental barrier, methenamine mandelate should be given to a pregnant woman only if the potential benefit outweighs the risk.
Methenamine is excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Gastrointestinal disturbances (nausea, stomach upset), generalized skin rash, dysuria, painful or difficult urination may occur occasionally with the use of methenamine preparations. Microscopic and rarely, gross hematuria have been described.
Minimize absorption by inducing vomiting or by gastric lavage followed by administration of activated charcoal. Administer orally fluids and alkalinize with sodium bicarbonate.
The average adult dose is 4 g a day given as one 1000 mg tablet or two 500 mg tablets after each meal and at bedtime. Children 6 to 12 years of age should receive half the adult dose; one 500 mg tablet, 4 times a day.
Methenamine Mandelate Tablets, USP 500 mg are blue, unscored, oval, film-coated, debossed with "436" on one side and plain on the other side.
Supplied in bottles of 100 (NDC 72162-2654-1)
Preserve in well-closed containers
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Repackaged/Relabeled by:
Bryant Ranch Prepack
Burbank, CA 91504
Manufactured for:
Westminster Pharmaceuticals, LLC
Nashville, TN 37217
Rev: 01/26
Methenamine Mandelate 500 mg Tablet #100
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| QR code link | QR Code |  dailymed.nlm.nih.gov/dailymed/search.cfm?query=72162-2654-1 | lbl721622654.jpg | |
| Data code | Code 128 | 7216226541 | lbl721622654.jpg | |
| Data code | Data Matrix | 0100363629103317211444981724013110LOT42832 | lbl721622654.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 260b0da6-d3d7-262f-a60f-d4b36d5f1b4d | Product name | 6 | 20251210 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 72162-2654-1 | Methenamine Mandelate | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 100 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69367-436-01 | EA - Each | 69367-436 | 08f4686d-9df6-48be-9463-5db703158c2d | 1 | 2026-05-22 |
| 69367-436-60 | EA - Each | 69367-436 | bfdbb239-46dc-42ee-a160-8a3d5cf412b1 | 1 | 2026-05-22 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 72162-2654 | 72162-2654-1 |
| 69367-436 |
Every source-derived ingredient row is available through these pages.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Methenamine Mandelate | METHENAMINE MANDELATE | Bryant Ranch Prepack | 23a57107-3709-4578-86e0-e5ca99435e7a | 2026-05-27 | Warnings, Adverse reactions | 72162-2654-1 72162-2654 72162265401 2bc5602b-03a3-44da-b860-644dd203ebfc 23a57107-3709-4578-86e0-e5ca99435e7a |
| Methenamine Mandelate | METHENAMINE MANDELATE | Westminster Pharmaceuticals, LLC | 1d76d132-6fd8-4139-989b-0bc38257ea3b | 2026-03-26 | Warnings, Adverse reactions | 69367-436 |
Adverse event summaries are temporarily unavailable. Other product information remains available.